Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • CG-806 for B-cell Tumors
    • CG-806 for Myeloid Tumors
    • APTO-253
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • CG-806 for CLL & NHL
    • CG-806 for AML
    • APTO-253 for AML & MDS
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events

Aptose Reports Results for the Second Quarter Ended June 30, 2019

Aug 06, 2019 4:00pm EDT

Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference

Jul 30, 2019 7:30am EDT

Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019

Jul 23, 2019 7:30am EDT

Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253

Jul 16, 2019 7:05am EDT

Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association

Jun 14, 2019 7:00am EDT

Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders

Jun 04, 2019 4:02pm EDT

Aptose Appoints Jotin Marango, M.D., Ph.D. as Chief Business Officer

Jun 03, 2019 9:00am EDT

Aptose Announces Closing of Public Offering of Common Shares

Jun 03, 2019 8:38am EDT

Aptose to Present at the Jefferies 2019 Healthcare Conference

May 31, 2019 8:00am EDT

Aptose Announces Pricing of Public Offering of Common Shares

May 30, 2019 9:01am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...20
    Next
    © 2021 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap